DiagnosisClinical DiagnosisNephropathic cystinosis (classic/infantile/early onset). The diagnosis of classic nephropathic cystinosis depends on the findings of renal tubular Fanconi syndrome in the untreated child in the first year of life, growth retardation after age six months, and progressive deterioration of renal glomerular function to end-stage renal disease (ESRD) over the first ten years of life [Gahl et al 2001, Gahl et al 2002]. Renal tubular Fanconi syndrome is established in the untreated child by documenting increased urinary losses of essential nutrients [Gahl et al 2001, Gahl et al 2002]. These include electrolytes (sodium, potassium, bicarbonate), minerals (calcium, phosphate, magnesium), glucose, amino acids, tubular protein including β2-microglobulin, and water. These renal losses result in symptoms such as hypophosphatemic rickets, evident both clinically and radiographically. Hypercalciuria and hyperphosphaturia can lead to medullary nephrocalcinosis detected by renal ultrasound examination. Growth retardation is usually apparent in the untreated child from age six months and is characterized by a growth rate that is 50%-60% of normal. Corneal cystine crystals cause photophobia and often blepharospasm and corneal erosions. A slit lamp examination of the cornea showing typical cystine crystals is diagnostic for cystinosis (Figure 1b). Corneal crystals may be present before age one year and are always present after age 16 months [Gahl et al 2000]. FigureFigure 1. Findings on slit lamp examination of the cornea in cystinosis
a. Band keratopathy in a 33-year-old treated with cysteamine eye drops, which dissolved the cystine crystals, but not the calcified band
b. Corneal crystals in an (more...)Intermediate nephropathic cystinosis (juvenile/late onset). This rare variant of cystinosis is characterized by the same renal and corneal events as those observed in untreated infantile nephropathic cystinosis, but with delayed onset and decreased severity. The tubular Fanconi syndrome can be so mild that it is not recognized, and rickets, growth retardation, electrolyte imbalance, and photophobia may be absent or clinically insignificant in childhood. In all cases, however, end-stage renal disease secondary to glomerular involvement occurs, usually between ages 15 and 25 years. Ocular (non-nephropathic) cystinosis. Untreated individuals with this variant never have impairment of renal function or growth. Photophobia is the sole symptom, although cystine crystals are present in the bone marrow and conjunctiva as well as in the cornea. Diagnosis is usually made on routine eye examination with a slit lamp. TestingLeukocyte cystine measurement. The clinical diagnosis of cystinosis should be confirmed by measurement of cystine concentrations in polymorphonuclear leukocytes. Measurement is best performed using mass spectrometry or the cystine binding protein assay, a competitive radioassay that detects nanomole quantities of cystine [Gahl et al 2001, Gahl et al 2002]. Individuals with nephropathic cystinosis generally have values of 3.0-23.0 nmol half-cystine/mg protein.Individuals with non-nephropathic cystinosis have values of 1.0-3.0 nmol half-cystine/mg protein. Heterozygotes have ≤1.0 nmol half-cystine/mg protein.Normal values are ≤0.2 nmol half-cystine/mg protein.Measurement by amino acid analysis (i.e., anion exchange chromatography) is less sensitive and can give spurious results if small amounts of leukocyte protein are available. Note: In preparing leukocytes for assay, care must be taken to avoid (1) a significant number of lymphocytes, which store only fivefold normal amounts of cystine compared with 50-fold normal amounts in polymorphonuclear leukocytes; and (2) contamination with red blood cells, which contribute protein but not cystine to the calculated cystine value. Both interfering substances produce artifactually low leukocyte cystine levels.Other cystine measurements. Cystinosis can also be diagnosed by the demonstration of increased cystine content in cultured fibroblasts or in the placenta at the time of birth [Gahl et al 2001].Crystals. On tissue biopsy of bone marrow, conjunctiva, kidney, liver, intestine, and other tissues, cystine crystals appear hexagonal or rectangular in shape and are birefringent under polarizing light [Gahl et al 2001, Gahl et al 2002]. Note: (1) The tissue should be fixed in 100% alcohol, as aqueous solutions can dissolve the crystals. (2) A skin biopsy does not contain crystals; neither do cultured cells of any type. Molecular Genetic TestingGene. CTNS is currently the only gene in which mutations are known to cause cystinosis. Clinical testing Table 1. Summary of Molecular Genetic Testing Used in CystinosisView in own windowGene SymbolTest MethodMutations Detected% of Northern Europeans with Nephropathic Cystinosis% of Non-Northern Europeans with CystinosisMutation Detection Frequency by Test Method <sup>1Test AvailabilityCTNSTargeted mutation analysis57-kb deletion 240%0%~100%Clinical Mutation panel optimized for the French-Canadian population 365%Unknown~100%Sequence analysisSequence variants 4UnknownUnknownUnknownDeletion / duplication analysis 5Detects 57-kb deletion and other partial and whole-gene deletions / duplicationsUnknownUnknownUnknown1. The ability of the test method used to detect a mutation that is present in the indicated gene
2. In the United States and northern European populations, approximately 50% of individuals with nephropathic cystinosis are homozygous for a 57-kb deletion that encompasses the first nine exons and introns of CTNS and interrupts exon 10 [Shotelersuk et al 1998, Town et al 1998, Touchman et al 2000]. In individuals with intermediate and non-nephropathic cystinosis, the 57-kb deletion can be present in the compound heterozygous state, along with a more "benign" mutation, but not in the homozygous state [Anikster et al 1999a, Forestier et al 1999].
3. 57-kb deletion, p.Trp138*, p.Thr7Phe, p.Gln128*, p.Trp182Arg, p.Leu158Pro, p.Gly308Arg, p.Asp205del, p.Ile133Pro; total of 55 mutations known [Kalatzis & Antignac 2003]. Testing for a panel of mutations optimized for the French-Canadian population is possible.
4. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations. Sequence analysis detects mutations other than the 57-kb deletion in northern Europeans and other population groups.
5. Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.Interpretation of test results. For issues to consider in interpretation of sequence analysis results, click here.Information on specific allelic variants may be available in Molecular Genetics (see Table A. Genes and Databases and/or Pathologic allelic variants).Testing StrategyTo confirm/establish the diagnosis in a proband. The diagnosis of renal tubular Fanconi syndrome is established by documenting: Renal tubular Fanconi syndrome. Increased urinary losses of essential nutrients including electrolytes (sodium, potassium, and bicarbonate), minerals (calcium, phosphate, and magnesium), glucose, amino acids, carnitine, and waterTypical cystine crystals in the cornea</sup>

Natural HistoryThe three types of cystinosis, i.e., nephropathic (classic renal and systemic disease), intermediate (a late-onset variant of nephropathic cystinosis), and non-nephropathic (clinically affecting only the cornea) are allelic disorders caused by CTNS mutations [Thoene et al 1999, Anikster et al 2000]. Nephropathic cystinosis. The clinical characteristics of untreated nephropathic cystinosis include those associated with poor growth, renal tubular Fanconi syndrome, renal glomerular failure, and non-renal involvement of a variety of tissues and organ systems. With effective cystine-depleting therapy, cystinosis was transformed from a progressive, fatal renal disease to a treatable chronic multisystemic disease, with life span increasing from about ten years to at least 50 years [Nesterova & Gahl 2008]. Growth. Infants with untreated nephropathic cystinosis are normal at birth. In untreated individuals, failure to grow is generally noticed between ages six and nine months. A high frequency of vomiting, poor appetite, and feeding difficulties, combined with renal losses of nutrients, causes poor nutrition and failure to thrive. Typically, infants are at the third percentile for height and weight at age one year [Gahl et al 2001, Gahl et al 2002]. Later, growth occurs at 60% of the normal rate. Bone age is usually delayed one to three years compared with chronologic age. Head circumference is normal for age.With early and optimal symptomatic and cystine-depleting therapy, individuals grow at a normal rate but their height often remains below the third centile and weight remains slightly above the third centile. Growth hormone administration improves height velocity in prepubertal children. Renal tubular Fanconi syndrome. Infants with untreated nephropathic cystinosis show signs of renal tubular Fanconi syndrome as early as age six months. The Fanconi syndrome involves failure of the renal tubules to reabsorb water, electrolytes, bicarbonate, phosphate, calcium, glucose, carnitine, amino acids, and tubular proteins. Individuals with untreated cystinosis have polyuria (2-6 L/day), polydipsia, dehydration, and hypochloremic metabolic acidosis, sometimes requiring hospitalization as a result of life-threatening hypovolemia, particularly during a gastrointestinal illness.
Hypophosphatemic rickets, characterized by high excretion of phosphate, elevated serum alkaline phosphatase, and bone deformities, make walking painful enough to delay ambulation. Hypocalcemia can cause seizures and tetany.
Severe hypokalemia can threaten cardiac conduction. Occasionally, hyponatremia and hypomagnesemia also occur.
Treatment with replacement of renal losses resolves the rickets, tetany, acidosis, and laboratory abnormalities, and cystine-depleting therapy begun just after birth can attenuate the renal tubular Fanconi syndrome [Kleta et al 2004a]. However, renal tubular damage present at the time of diagnosis (i.e., age ~1 year) is irreversible. Renal glomerular failure. In the natural history of untreated nephropathic cystinosis, glomerular function gradually deteriorates, resulting in renal failure at approximately age ten years [Gahl et al 2001, Gahl et al 2002].The serum creatinine concentration may not exceed 1.0 mg/dL until age five years, but once it rises, it increases exponentially. Many affected individuals have significant proteinuria, sometimes in nephrotic ranges, along with granular casts and microhematuria.
Early treatment with cystine-depleting therapy (i.e., oral cysteamine) slows or stops the progression of glomerular damage and can delay or eliminate the need for renal transplantation [Kleta et al 2004a], which is successful because cystine does not accumulate in the cells of the donated kidney.Non-renal involvement. Without therapy, cystine accumulation occurs in virtually all organs and tissues, including bone marrow, liver, intestine, muscle, brain, spleen, eye, thyroid, pancreas, and testes. Without therapy, several complications of cystinosis occur prior to renal transplantation: Infants and children can have poor appetite and vomit regularly, usually in the morning. Children with cystinosis have mildly altered craniofacial morphology, reduced airway dimensions, delayed dental development, and delayed eruption of permanent teeth [Bassim et al 2010].Photophobia develops when the cornea becomes packed with crystals, generally at the end of the first decade of life. Affected individuals typically develop hypothyroidism at the end of the first decade of life. Sweating is impaired and affected individuals can suffer heat prostration [Gahl et al 2001, Gahl et al 2002]. Intelligence is normal in cystinosis, although neurobehavioral abnormalities, including visual memory defects, have been reported [Gahl et al 2001, Gahl et al 2002]. Benign intracranial hypertension presents with headaches and papilledema [Dogulu et al 2004].Puberty is generally delayed one to two years. Untreated males exhibit primary hypogonadism [Chik et al 1993].No male with untreated cystinosis has fathered a child; a few females with untreated cystinosis have delivered healthy children [Haase et al 2006].It is currently not known whether diligent cysteamine treatment can prevent primary hypogonadism in males. Late-onset abnormalities. Well after renal transplantation, i.e., at approximately age 20 to 40 years, another set of complications can occur from the longstanding accumulation of cystine crystals in non-renal organs in individuals not treated with cysteamine [Servais et al 2008].Increased cystine content in the muscles causes vacuolar myopathy in 60% of individuals [Gahl et al 2007]. Generalized myopathy leads to progressive muscle wasting and weakness (Figures 2a, 2c, 2d) [Ishak et al 1994]. Oral motor dysfunction causes swallowing and feeding difficulties [Trauner et al 2001, Sonies et al 2005]. Electromyography demonstrates a myopathic pattern.Extrinsic chest muscle impairment causes extraparenchymal restriction of ventilation leading to pulmonary insufficiency with decreased values of FVC and FEV1 on routine pulmonary function tests [Anikster et al 2001].Gastrointestinal findings can include reflux, dysmotility, esophagitis, gastric/duodenal ulcers, hepatomegaly with nodular regenerating hyperplasia of the liver with portal hypertension, exocrine pancreatic insufficiency [DiDomenico et al 2004, O’Brien et al 2006], inflammatory bowel disease, bowel perforation, and peritonitis [Gahl et al 2007]. Cardiovascular manifestations can include arteriopathy caused by the combination of vascular calcifications and obstructive atherosclerosis with hypercholesterolemia (Figure 2e) [Ueda et al 2006]; ESRD and renin-dependent hypertension; dilated cardiomyopathy; and aortic aneurysms. All of these factors contribute to cardiovascular morbidity and increase the risk for myocardial infarction and neurovascular incidents.Metabolic bone disease develops as a result of direct deposition of cystine crystals in bone, mineral imbalance, and renal osteodystrophy prior to renal transplantation [Zimakas et al 2003].Hypercoagulopathy and hypocoagulopathy occur as a result of renal failure and platelet aggregation dysfunction [Nesterova & Gahl 2008]. CNS calcifications (Figure 2f), benign intracranial hypertension with non-absorptive hydrocephalus, and parenchymal deterioration of the central nervous system with cerebral atrophy lead to various degrees of encephalopathy [Gahl et al 2001, Gahl et al 2002]. Occasionally, cerebrovascular incidents with paresis or pseudobulbar palsy occur [Gahl et al 2007].Intellectual abilities are low-normal; affected children have mainly average school performance. They have impaired visual and spatial cognition with preserved language and intellectual function [Spilkin et al 2007]. Their distinctive behavioral and psychosocial difficulties stem from the chronic disease: ESRD, renal dialysis, prolonged hospitalizations, and treatment with multiple therapeutic agents, including steroids [Ballantyne & Trauner 2000, Delgado et al 2005].Late ocular complications. Crystal deposition in the anterior chamber, iris, ciliary body, choroid, fundus, and optic nerve manifests as [Tsilou et al 2007]:Anterior segment problems. Crystals in the anterior lens surface, band keratopathy (Figure 1a), peripheral corneal neovascularization, and posterior synechiae Posterior segment problems. Pigmentary retinopathy with degeneration of the photoreceptors that contributes to the impaired visual function in the late stage of the disease [Tsilou et al 2002]. Electroretinogram (ERG) is used to confirm the retinopathy.FigureFigure 2
a. A 37-year-old man with nephropathic cystinosis, thin habitus
b. Gastrostomy tube
c. Clawed hand with wasting of thenar and hypothenar eminences and interosseous muscles
d. Muscle wasting in upper trunk
e. (more...)Intermediate cystinosis. All the early manifestations of untreated nephropathic cystinosis, including the renal tubular Fanconi syndrome, growth delay, photophobia, and glomerular failure, occur in individuals with untreated intermediate cystinosis, but at a later age, mostly during adolescence. Non-nephropathic cystinosis. Individuals with untreated non-nephropathic cystinosis experience only photophobia. Histopathology. Electron microscopy of the glomeruli reveals fusion of foot processes, thickening of Bowman’s membrane, and localization of cystine crystals in interstitial cells. Cystinotic glomeruli show focal glomerulosclerosis [Mahoney & Striker 2000]. Pathophysiology. The pathophysiology of renal tubular Fanconi syndrome is under investigation. Several mechanisms have been suggested: Inhibition of the Na-phosphate cotransporter resulting from cystine accumulation in the proximal tubular cells with depletion of intracellular ATP [Baum 1998, Kleta & Gahl 2002, Park et al 2002]Degeneration of the proximal tubules, which is well documented in nephropathic cystinosis [Mahoney & Striker 2000]Inappropriately increased apoptosis, leading to progressive cell death in proximal tubules resulting in atubular glomeruli and renal failure [Larsen et al 2010]

Genotype-Phenotype CorrelationsSome genotype-phenotype correlations can be made:Within the group of individuals with nephropathic cystinosis, truncating CTNS mutations, as well as the 57-kb deletion, result in severe, classic (early-onset or infantile type) disease [Shotelersuk et al 1998, Attard et al 1999]. Individuals with apparent residual activity (i.e., lower levels of cystine accumulation in leukocytes) often have missense mutations in CTNS [Attard et al 1999]. Individuals with intermediate cystinosis (i.e., nephropathic but late-onset) or non-nephropathic cystinosis (i.e., corneal and bone marrow crystals but no renal involvement) have one severe CTNS mutation, typical for nephropathic cystinosis, and one mild mutation. The mild mutations include p.Gly197Arg and c.853-3C>G [Anikster et al 1999b]. The organ specificity in benign cystinosis may result from tissue-specific splicing factors.The p.Ser139Phe mutation may cause the juvenile phenotype [Macías-Vidal et al 2009]. Deletions of CTNS and its flanking genes may lead to contiguous gene deletion syndromes with more complex phenotypes than those of classic cystinosis [Kalatzis & Antignac 2003]. For example, the 57-kb deletion on chromosome 17p13 extends into TRPV1 causing dysregulation of TRPV1 transcription in peripheral blood mononuclear cells [Freed et al 2011].Heterozygotes have 50% of transport capacity in their lysosomes [Thoene 1995, Gahl et al 2002].Loss of cystinosin may result in the unregulated activation of other transporters and pathways, including redox-based signaling or protein cysteinylation [Bellomo et al 2010]. Other lysosomal functions may also be impaired in cystinosis [Wilmer et al 2010]. Recent studies of whole-genome expression profiles in peripheral blood samples from people with cystinosis identified modifier genes and pathways associated with nephropathic cystinosis; further investigation is needed to confirm the role of these genes in modulating the cystinosis phenotype [Sansanwal et al 2010].

Differential DiagnosisUntreated nephropathic cystinosis is the most common identifiable cause of the renal tubular Fanconi syndrome in childhood. Other causes:Wilson disease is a disorder of copper metabolism that can present with hepatic, neurologic, or psychiatric disturbances or a combination of these, from age three to over 50. Diagnosis depends in part upon the detection of low serum copper and ceruloplasmin concentrations and increased urinary copper excretion. Mutations in ATP7B are causative. Inheritance is autosomal recessive. Oculocerebrorenal syndrome of Lowe is found in males and involves the eyes (cataracts, glaucoma, decreased visual acuity), central nervous system (hypotonia, intellectual disability), and kidneys (Fanconi syndrome). Slowly progressive glomerulosclerosis and renal failure are often noted after age ten years. It is diagnosed by demonstrating reduced (<10% of normal) activity of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in cultured skin fibroblasts. Mutations in the responsible gene, OCRL1, are detectable in most males and carrier females. (Mutations in OCRL1 can also cause Dent's disease, which can present with findings typical for renal Fanconi syndrome.) Inheritance is X-linked. Galactosemia is a disorder of galactose metabolism that can result in feeding problems, failure to thrive, hepatocellular damage, bleeding, and sepsis in untreated infants. It is most often caused by deficient activity of the enzyme galactose-phosphate uridyltransferase (GALT), and can be diagnosed by measurement of erythrocyte GALT enzyme activity and by isoelectric focusing of GALT. Molecular genetic testing of GALT is possible for individuals with biochemically confirmed galactosemia. Glycogen storage disease type I presents mainly with hepatomegaly and hypoglycemia. Tyrosinemia type I presents with severe liver disease in infancy and shows abnormal tyrosine metabolites on organic acid analyses. Glucosuria associated with renal tubular Fanconi syndrome can result in misdiagnosis as diabetes mellitus. Polyuria often leads to a misdiagnosis of diabetes insipidus (see Nephrogenic Diabetes Inspidus). Electrolyte abnormalities can suggest Bartter syndrome. The rickets of cystinosis can falsely suggest vitamin D deficiency.Multiple myeloma can cause photophobia and corneal crystals similar to those in ocular cystinosis [Kleta et al 2004b]. Note to clinicians: For a patient-specific ‘simultaneous consult’ related to this disorder, go to , an interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration or institutional access required).Nephropathic cystinosisIntermediate cystinosisNon-nephropathic cystinosis

ManagementEvaluations Following Initial DiagnosisAt the time of diagnosis, the following evaluations are recommended in all individuals with cystinosis regardless of age:Height and weight, plotted on age-appropriate growth chartsRenal tubular and glomerular function, especially serum concentrations of creatinine, phosphate, bicarbonate, and potassium; and urine concentrations of creatinine, phosphate, bicarbonate, potassium, glucose, and protein Glomerular filtration rate (GFR) or creatinine clearance testThyroid function studies Lipid panel Renal ultrasound examination for evaluation of nephrocalcinosis Ophthalmologic evaluation, including slit lamp examination of the cornea to assess corneal involvement, ERG to assess retinal involvement, and fundoscopic examination for possible intracranial hypertension The following are recommended in individuals who are initially diagnosed at an older age:In pre- and postpubertal males, measurement of serum concentration of testosterone, FSH, and LH Glucose tolerance test to assess for diabetes mellitus if symptoms are presentTreatment of ManifestationsIt is recommended that a multidisciplinary team that includes nephrologists, metabolic disease specialists, ophthalmologists, neurologists, gastroenterologists, nutritionists and psychologists manage individuals with cystinosis.Renal tubular Fanconi syndrome is treated by replacement of renal losses: For children, free access to water and bathroom privileges and supplementation with citrate to alkalinize the blood Phosphate replacement to prevent and heal hypophosphatemic rickets; vitamin D supplementation to assist the gastrointestinal absorption of phosphate Potassium, calcium, magnesium, or carnitine supplementation as neededCareful attention to fluid and electrolyte replacement during gastrointestinal illnesses. (Obligatory urinary losses amount to 2-6 L electrolyte-rich water per day.) Reduction of cellular cystine concentration through treatment with the cystine-depleting agent cysteamine (see Prevention of Primary Manifestations) ACE inhibitors could be used to slow the progression of renal insufficiency attributed to proteinuria [Levtchenko et al 2004]. Renal transplantation. Renal replacement is usually indicated when the creatinine clearance falls below 20 mL/min/1.73 m² and azotemia and hypertension rapidly progress. The time frame for appropriate renal replacement is the point at which the reciprocal serum creatinine value plotted against age reaches approximately 0.1. Symptoms often determine the exact time of transplantation.Ophthalmologic problems are treated symptomatically and with cystine-depleting agents: The photophobia, resulting from corneal crystal accumulation, can be ameliorated by sun avoidance, dark glasses, and lubrication with over-the-counter eyedrops (see Prevention of Primary Manifestations). Corneal transplantation is very rarely required for intractable pain resulting from recurrent corneal ulcerations. Retinal involvement is irreversible. Growth for children with cystinosis requires good nutrition, adequate phosphate supplementation, and robust intracellular cystine depletion (see Prevention of Primary Manifestations): Nutrition must be adequate for growth. Growth hormone therapy has proven beneficial for children with cystinosis in providing catch-up growth and bringing them into the normal percentiles for height [Gahl et al 2001, Wühl et al 2001, Gahl et al 2002]. Early and diligent treatment with supplements and oral cysteamine can obviate the need for growth hormone [Kleta et al 2004a]. Other Oral L-thyroxine replacement for hypothyroidism Insulin for diabetes mellitus Testosterone to induce secondary sexual characteristics in males with primary hypogonadism Specific exercises for the muscle deterioration and swallowing difficulties of older individuals with cystinosis; hand tendon transfer has been partially successful in improving strength. Speech therapy and physical therapyStandard treatment for benign intracranial hypertension; other central nervous system complications are irreversible. Feeding via gastrostomy for those with dysphagia, poor nutrition, and risk of aspiration (Figure 2b)Prevention of Primary ManifestationsCystine depletion therapy with cysteamine bitartrate (Cystagon^®) has revolutionized the management and prognosis of people with nephropathic cystinosis. Cysteamine is now the treatment of choice for cystinosis throughout the world. This free thiol can deplete cystinotic cells of more than 90% of their cystine content [Kleta & Gahl 2004]. Wilmer et al [2011] found that cysteamine also increased intracellular glutathione levels and restored the glutathione redox status of cystinotic cells. Cysteamine therapy should be considered for all affected individuals, regardless of age and transplantation status [Gahl et al 2007]. With early, diligent treatment many individuals with cystinosis have survived into their twenties without the need for renal transplantation [Gahl et al 2002].Regular and diligent cysteamine therapy prevents or delays end-stage renal disease (ESRD) [Markello et al 1993] and hypothyroidism, enhances growth, and depletes muscle parenchyma of cystine [Gahl et al 2002]. It is critical to initiate cysteamine therapy immediately after diagnosis to allow for kidney growth and acquisition, rather than loss, of renal function [Kleta et al 2004a]. Cystagon^® is taken orally every six hours at 60 to 90 mg of free base per kg per day (1.3 to 1.95 g/m² per day). The recommended adult dose is 500 mg free base every six hours; however, for both children and adults, the dose is titrated to reduce, if possible, leukocyte cystine concentration (measured 5-6 hours after a dose) to below 1.0 nmol half-cystine/mg protein [Belldina et al 2003, Kleta & Gahl 2004, Kleta 2006]. Side effects of cysteamine treatment include nausea and vomiting, in part because of its repulsive odor and taste [Schneider 2004]. Cysteamine increases gastrin synthesis and gastric acid production. Omeprazole may be of benefit for oral cysteamine treatment [Dohil et al 2003].With long-term cystine-depleting therapy most late complications of cystinosis can be avoided.Despite diligent oral cysteamine therapy, cysteamine hydrochloride eyedrops are required to achieve sufficient tissue concentration to dissolve corneal crystals [Gahl et al 2000]. Cysteamine eyedrops are given ten to 12 times per day as a 0.55% solution with benzalkonium chloride 0.01% as a preservative [Tsilou et al 2007]. With good compliance photophobia is relieved within weeks (Figures 1b, 1c) [Kaiser-Kupfer et al 1987, Gahl et al 2000]. Systemic cysteamine treatment ameliorates or postpones retinal deterioration [Tsilou et al 2006]. Cysteamine eyedrops remain investigational.Prevention of Secondary ComplicationsPost-transplant patients should be monitored for the signs of immunodeficiency and infection. Carnitine supplementation is used in some patients to improve muscle strength.Treatment with proton pump inhibitors, such as omeprazole, relieves cysteamine-induced gastric acid hypersecretion and improves gastrointestinal symptoms [Osefo et al 2009]. SurveillanceClinical and laboratory examinations should be performed in individuals with nephropathic cystinosis according to disease severity and may include renal, endocrinologic, ophthalmologic, neurologic, and cardiac examinations [Kleta et al 2005]:Evaluation by a nephrologist every three to six months depending on the severity of renal impairmentRenal function tests, electrolytes, and thyroid function tests at least every three to six months in those who are stable Serum concentration of calcium, phosphate, alkaline phosphatase and intact parathyroid hormone. Plain bone radiographs as well as DEXA scans to detect osteopenia and bone fragility predisposing to fractures, starting as soon as diagnosis is made and continued throughout the course of the disease Ophthalmologic evaluation with fundoscopic examination to screen for increased intracranial pressure every one to two years for those being treated appropriatelyFasting blood glucose concentration throughout the course of the disease and testosterone concentration (in males) every two to three years, starting before pubertyIn advanced disease (i.e., poorly treated adults) and in late stages of disease, perform every two to three years: Chest CT for detection of coronary and other vascular calcificationECGBrain CT or MRI for evaluation of cerebral atrophy or calcificationsEvaluation for the presence of progressive muscle weakness and swallowing difficulties using electromyography (EMG), oral sensorimotor examination, and modified barium swallowing studies with videofluoroscopy Pulmonary function testsNeurologic and neurocognitive evaluations including visual-motor integration, visual memory, planning, sustained attention, and motor speed beginning at age seven to eight years [Besouw et al 2010a]. Agents/Circumstances to AvoidAvoid the following:Dehydration, which compromises remaining renal functionSun exposure, which can exacerbate photophobiaEvaluation of Relatives at RiskRelatives at risk (e.g., newborn sibs of a proband) can undergo biochemical testing and/or molecular genetic testing (if the disease-causing mutations in the family are known). Early diagnosis allows for early treatment to prevent life-threatening complications of cystinosis.See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.Pregnancy ManagementPregnancies in women with cystinosis are at a higher risk for premature delivery and must be monitored closely [Ramappa & Pyatt 2010]. For women who are post-transplantation, the abdominal renal allograft creates mechanical issues. For women who have not undergone transplantation, fluid and electrolyte status require careful management. Therapies Under InvestigationClinical trials of a formulation of cysteamine requiring twice-daily oral administration to improve compliance are ongoing.Bone marrow-derived stem cell transplantation in mice improved chronic kidney disease [Yeagy et al 2011].Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.OtherDevelopment of a newborn screening test for cystinosis will potentially allow broader therapeutic success [Nesterova & Gahl 2008]. Two methods have been proposed: tandem mass spectrometry for the determination of derivative seven-carbon (C7) sugars in dried blood spots (DBS), which detect homozygosity for the CTNS 57-kb deletion and molecular genetic testing for the most common CTNS mutations [Wamelink et al 2011]. Therapies proven to be ineffective include dietary restriction of sulfur-containing amino acids, supplementation with ascorbic acid, and the use of dithiothreitol.

Molecular GeneticsInformation in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.Table A. Cystinosis: Genes and DatabasesView in own windowGene SymbolChromosomal LocusProtein NameLocus SpecificHGMDCTNS17p13​.2CystinosinCTNS homepage - Mendelian genesCTNSData are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.Table B. OMIM Entries for Cystinosis (View All in OMIM) View in own window 219750CYSTINOSIS, ADULT NONNEPHROPATHIC 219800CYSTINOSIS, NEPHROPATHIC; CTNS 219900CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE 606272CYSTINOSIN; CTNSNormal allelic variants. Normal CTNS is 26 kb in length and has 12 exons with a coding region of 1104 bp [Town et al 1998]. Several normal allelic variants have been reported. Pathologic allelic variants. At least 80 different mutations including promotor mutations in CTNS have been reported; they are found in different combinations in individuals with cystinosis [Shotelersuk et al 1998, Town et al 1998, Attard et al 1999, McGowan-Jordan et al 1999, Thoene et al 1999, Anikster et al 2000, Kleta et al 2001, Phornphutkul et al 2001, Kalatzis et al 2002, Kiehntopf et al 2002, Mason et al 2003]. The mutations include missense, nonsense, and splice site mutations, deletions, and insertions leading to downstream stop codons or abolition of splice sites [Kiehntopf et al 2002]. The missense mutations are usually present within transmembrane regions [Anikster et al 1999b]. There are no mutational hot spots. By far the most common mutation (50% of affected individuals) is the 57-kb deletion involving exons 1-9 and part of exon 10; this mutation apparently represents a founder effect [Shotelersuk et al 1998]. Another relatively common mutation is p.Trp138*. A higher incidence of infantile cystinosis was reported in the French province of Brittany, with an incidence of 1:26000. The splice site mutation c.898_900+24del27 segregates in certain unrelated families [Kalatzis et al 2002]. (For more information, see Table A.) Table 2. CTNS Pathologic Allelic Variants Discussed in This GeneReviewView in own windowDNA Nucleotide Change
(Alias ¹)Protein Amino Acid ChangeReference Sequences g.36,254_93,510del
(57-kb del) ^{2--AF168787c.198_218del
(c.198del21bp or 537del21)p.Ile67_Pro73delNM_004937​.2
NP_004928​.2c.414G>Ap.Trp138*c.473T>Cp.Leu158Proc.589G>Ap.Gly197Argc.613G>Ap.Asp205Asnc.696dupC
(c.696_697insC or 1035insC)p.Val233Argfs*63c.853-3C>G-- 3c.898_900+24del27--See Quick Reference for an explanation of nomenclature. GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​.hgvs.org). 1. Variant designation that does not conform to current naming conventions 2. Touchman et al [2000]3. Anikster et al [2000]Normal gene product. Cystinosin, the protein product of CTNS, is a 367-amino acid peptide with seven transmembrane and two lysosomal targeting motifs, a 128 amino-acid N-terminal region bearing seven potential N-glycosylation sites, and a ten amino-acid cytosolic C-terminal tail [Town et al 1998, Kalatzis & Antignac 2002, Kalatzis & Antignac 2003]. Cystinosin is expressed in the cells of virtually all tissues. Cystinosin transports the disulfide amino acid cystine out of the lysosome and into the cytoplasm [Gahl et al 2002, Kleta & Gahl 2002]. Cystinosin is highly conserved between man and mouse [Cherqui et al 2002].Abnormal gene product. The 57-kb deletion allele produces no CTNS mRNA, while most other alleles produce some residual mRNA [Shotelersuk et al 1998]. The mutant alleles of CTNS are predicted to produce truncated cystinosin in the case of severely affected individuals and to produce cystinosis that retains some residual function in the case of mildly affected individuals.}